MedTrace Logo

Circulating Tumor DNA as Marker of Therapeutic Efficacy in Breast Cancer Patients

NCT03881384 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-06-04

No results posted yet for this study

Summary

In nonmetastatic local advanced breast cancer patients, we are going to investigate whether circulating tumor DNA (ctDNA) detection can reflect the tumor response to neoadjuvant chemotherapy (NCT) and detect minimal residual disease after surgery.

Conditions

  • Breast Neoplasms

Interventions

OTHER

ctDNA level during neoadjuant chemotherapy

Draw blood from each enrolled patient every time before chemotherapy and measure the ctDNA level in plasma.

Sponsors & Collaborators

  • First Affiliated Hospital Xi'an Jiaotong University

    lead OTHER

Principal Investigators

  • Jianjun He, PhD · First Affiliated Hospital of Xian Jiaotong University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2021-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03881384 on ClinicalTrials.gov